Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2015

01-04-2015 | Introduction to Review Articles

Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor

Author: Hirotaka Iwase

Published in: International Journal of Clinical Oncology | Issue 2/2015

Login to get access

Excerpt

Metastatic breast cancer (MBC) is not a curable disease except for local recurrence or oligo-metastasis in the non-visceral organs. In fact, the 10-year survival rate after chemotherapy is approximately 5 %, and, for patients who survive, the complete response rate beyond 20 years is only 2–3 % [1, 2]. Consequently, the purpose of treatment is the prolongation of survival and the improvement of quality of life (QOL). By means of advances in treatment with the advent of a large number of new drugs, survival after recurrence has been gradually improved since the 1990s [3, 4]. …
Literature
1.
Greenberg PA, Hortobagyi GN, Smith TL et al (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer (translated from Eng). J Clin Oncol 14(8):2197–2205 (in Eng)PubMed
2.
Rahman ZU, Frye DK, Smith TL et al (1999) Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference (translated from Eng). Cancer 85(1):104–111 (in Eng)CrossRefPubMed
3.
Gennari A, Conte P, Rosso R et al (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies (translated from Eng). Cancer 104(8):1742–1750 (in Eng)CrossRefPubMed
4.
Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? (translated from Eng). Cancer 100(1):44–52 (in Eng)CrossRefPubMed
5.
Fossati R, Confalonieri C, Torri V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women (translated from Eng). J Clin Oncol 16(10):3439–3460 (in Eng)PubMed
6.
Gralow JR (2005) Optimizing the treatment of metastatic breast cancer (translated from Eng). Breast Cancer Res Treat 89(Suppl 1):S9–S15 (in Eng)CrossRefPubMed
7.
Tot T, Tabar L (2011) The role of radiological–pathological correlation in diagnosing early breast cancer: the pathologist’s perspective (translated from Eng). Virchows Arch 458(2):125–131 (in Eng)CrossRefPubMed
8.
Lianidou ES, Mavroudis D, Georgoulias V (2013) Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer (translated from Eng). Br J Cancer 108(12):2426–2432 (in Eng)CrossRefPubMedCentralPubMed
9.
Rothe F, Laes JF, Lambrechts D et al (2014) Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer (translated from Eng). Ann Oncol 25(10):1959–1965 (in Eng)CrossRefPubMed
10.
Yamamoto N, Watanabe T, Katsumata N et al (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer (translated from Eng). J Clin Oncol 16(7):2401–2408 (in Eng)PubMed
11.
Iwase H (2008) Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer (translated from Eng). Breast Cancer 15(4):278–290 (in Eng)CrossRefPubMed
12.
Osborne CK (1998) Tamoxifen in the treatment of breast cancer (translated from Eng). N Engl J Med 339(22):1609–1618 (in Eng)CrossRefPubMed
13.
Howell A, Robertson JF, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial (translated from Eng). J Clin Oncol 22(9):1605–1613 (in Eng)CrossRefPubMed
14.
Di Leo A, Jerusalem G, Petruzelka L et al (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer (translated from Eng). J Clin Oncol 28(30):4594–4600 (in Eng)CrossRefPubMed
15.
Byrne MJ, Gebski V, Forbes J et al (1997) Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian–New Zealand Breast Cancer Trials Group (translated from Eng). J Clin Oncol 15(9):3141–3148 (in Eng)PubMed
16.
Haddow A, Watkinson JM, Paterson E et al (1944) Influence of synthetic oestrogens on advanced malignant disease (translated from Eng). Br Med J 2(4368):393–398 (in Eng)CrossRefPubMedCentralPubMed
17.
Ellis MJ, Gao F, Dehdashti F et al (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study (translated from Eng). JAMA 302(7):774–780 (in Eng)CrossRefPubMedCentralPubMed
18.
Iwase H, Yamamoto Y, Yamamoto-Ibusuki M et al (2013) Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study (translated from Eng). Br J Cancer 109(6):1537–1542 (in Eng)CrossRefPubMedCentralPubMed
19.
Yardley DA, Noguchi S, Pritchard KI et al (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis (translated from Eng). Adv Ther 30(10):870–884 (in Eng)CrossRefPubMedCentralPubMed
20.
Rocca A, Farolfi A, Bravaccini S et al (2014) Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer (translated from Eng). Expert Opin Pharmacother 15(3):407–420 (in Eng)CrossRefPubMed
21.
Burzykowski T, Buyse M, Piccart-Gebhart MJ et al (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer (translated from Eng). J Clin Oncol 26(12):1987–1992 (in Eng)CrossRefPubMed
22.
Robertson JF, Howell A, Gorbunova VA et al (2005) Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant (translated from Eng). Breast Cancer Res Treat 92(2):169–174 (in Eng)CrossRefPubMed
Metadata
Title
Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor
Author
Hirotaka Iwase
Publication date
01-04-2015
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0795-6

Other articles of this Issue 2/2015

International Journal of Clinical Oncology 2/2015 Go to the issue

Special Article

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

Original Article

Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer

Original Article

Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy

Original Article

The present state and perception of young women with breast cancer towards breast reconstructive surgery

Special Article

Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer

Review Article

Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits